LIXT

Lixte Biotechnology Holdings Inc. (LIXT) | Rumor.io

Lixte Biotechnology Holdings

LIXT

Attention (50-day avg)0%

Attention rank (50-day avg)#4,360

Bullish sentiment (50-day avg)100%

Price to earnings ratio-2.84

Market capitalization62.2M

Earnings per share-1.14

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-6M

Social

What share of all stock conversation is about LIXT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Jul 6

Lixte Biotechnology Holdings, Inc. has completed a corporate name change to NOMAD Power Solutions, Inc. and will begin trading under the new Nasdaq symbol NMAD.
The market has been experiencing a significant decline in the stock price of LIXT, with a drop of 5.997392438070404% to $7.21.
The name change and the market's reaction to it may be a significant event in determining the future market price of NOMAD Power Solutions, Inc.

Generated by AI

Sentiment

Of the messages about LIXT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	96.55% +6.65
Bearish	—	—	—	3.45% -6.65

Bullish· Jul 10

LIXT's recent announcements and funding have significantly boosted its short-term growth potential.
The company's advancements in clinical trials and securing new partnerships are driving the stock's rise.
LIXT's technology is currently underpriced, and a decent volume push could take the stock to $4 and then $5.

Bearish· Jul 3

Lixte Biotechnology Holdings, Inc. (LIXT) may experience a significant price drop if it fails to hold above $3.38.
Short covering at $3.20 led to a decline in LIXT's price, indicating a lack of buyers and a potential lack of profit.
LIXT has received a large "smart money" net outflow, resulting in a $526.41K loss and a 40.10% price change.

Generated by AI

Topics

Of the messages about LIXT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	81.36%
Technical Analysis	0%	0%	0%	4.3%
Analysts	0%	0%	0%	13.62%
Controversies	0%	0%	0%	0.72%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%

Announcements· Apr 17

Lixte Biotechnology Holdings, Inc. (LIXT) is positioning its LB-100 as a novel approach in the cancer treatment landscape.
The company is advancing precision oncology with LB-100 and strengthening its position through a partnership with Liora Technologies.
LIXT's LB-100 is a potential treatment for cancer, with the company positioning it as a novel approach in the field of oncology.

Technical Analysis· Jul 4

LIXT's price surged from $2 to $4, with a significant increase in volume and a strong RSI reading, indicating explosive momentum.
The stock's chart pattern showed a bullish breakout, with the RSI hitting the sweet spot and volume skyrocketing, catching the attention of chart watchers.
LIXT's technical analysis suggests strong momentum, with the stock breaking through key resistance and RSI signaling super strength, indicating a potential continuation of the bullish trend.

Generated by AI

Community

Of the messages about LIXT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	40.48%
Newcomers	0%	0%	0%	59.52%

Regulars· Jul 3

Lixte Biotechnology Holdings, Inc. ($LIXT) saw a 55% increase after closing a $5M private placement and experiencing a surge in volume, nearly 9M traded.
The company's lead drug, LB-100, is showing early promise in cancer research, with a low float and fresh capital signaling a bright future in biotech.
The stock's strong momentum is attributed to its bullish chart patterns, with the RSI (Relative Strength Index) signaling strength and a breakout in volume, indicating a potential liftoff setup.

Newcomers· Jul 3

The newcomers are focused on the potential for Lixte Biotechnology Holdings, Inc. (LIXT) to reach prices above $4 and possibly even $5 per share.
They are concerned about taking profits and managing risk, as the stock's volume is "insane" and it can come down quickly.
The newcomers are predicting a "green day" and expecting LIXT to hit $4 per share, with one user even claiming it will fly on VWAP support.

Generated by AI

Huda Almashhadany Joins Team as Chief of Product & VP of Operations,Company Names Brian Dockendorf as Director of Service Boca Raton, Fla., July 15, 2026 (GLOBE NEWSWIRE) -- NOMAD Power Solutions, Inc. (“NOMAD” or the “Company”) (Nasdaq: NMAD) today announced the appointment of Huda Almashhadany as Chief of Product & Vice President of Operations and Brian Dockendorf as Director of Service at the Company’s principal operating subsidiary, Nomad Transportable Power Systems Inc., a leading provider

2mo agoYahoo Finance

AI Energy Pivot Complete: LIXTE Biotechnology Finishes Corporate Rebrand to NOMAD Power Solutions, Begins Trading Under Nasdaq: NMAD

Detailed price information for Fluence Energy Inc Cl A (FLNC-Q) from The Globe and Mail including charting and trades.

2mo agoThe Globe and Mail

LIXTE Completes Corporate Name Change to NOMAD Power Solutions, Inc.; To Begin Trading Under New Nasdaq Symbol NMAD

-- New Corporate Identity Reflects Strategic Transition into AI Energy Infrastructure Equipment & Services Sector Following Acquisition of NOMAD Transportable Power Systems -- BOCA RATON, Fla., July 06, 2026 (GLOBE NEWSWIRE) -- NOMAD Power Solutions, Inc. (“NOMAD” or the “Company”), today announced that it has completed its name change from LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) to NOMAD Power Solutions, Inc (Nasdaq: NMAD). The Company’s common stock will begin trading today under its

2mo agoYahoo Finance

12 Health Care Stocks Moving In Thursday's After-Market Session - Seer (NASDAQ:SEER), Universe Pharmaceut

Gainers Seer (NASDAQ:SEER) stock moved upwards by 33.3% to $2.16 during Thursday's after-market session. The market value of their outstanding shares is at $89.6 million. Universe Pharmaceuticals (NASDAQ:UPC)

2mo agoBenzinga

Also Discussed

Investors talking about LIXT also mention

#	Name	Attention
1	Immix Biopharma, Inc.IMMX	0.03%+0.03
2	HCDI - Harbor Custom Development, Inc.	——
3	Guardforce AI Co., Ltd.GFAI	0%0
4	Longeveron Inc. Class A Common StockLGVN	0%0
5	Kidpik Corp.PIK	0%new
6	REalloys Inc.BLBX	0%0
7	Biofrontera Inc.BFRI	0%0
8	T Stamp Inc. Class A Common StockIDAI	0%new
9	NeuroSense Therapeutics Ltd.NRSN	0%0
10	TCBP - TC Biopharm (Holdings) Plc	——

Lixte Biotechnology Holdings Inc.

Industrials
Electrical Equipment & Parts

Lixte Biotechnology Holdings Inc. is a biotechnology company specializing in the research and development of treatments aimed at addressing various forms of cancer and other serious diseases. The primary function of Lixte is to innovate in the field of drug development by focusing on novel compounds that can serve as potential therapeutics. Notably, the company concentrates on identifying and developing small molecule inhibitors that target specific pharmacological pathways involved in cancer progression and other diseases. Lixte operates primarily within the biotechnology and pharmaceutical sectors, holding significance for its contribution to potentially groundbreaking cancer therapies. By focusing on a niche market in oncology and the broader healthcare industry, Lixte Biotechnology Holdings Inc. plays a critical role in advancing scientific research and offering new hope in the fight against complex diseases. Its activities exemplify the intersection of cutting-edge science and the quest for effective clinical solutions in a highly dynamic and innovative sector.

Website

Location

5 Pilgrim Park Rd

Waterbury, VT, 05676

United States

Social

What share of all stock conversation is about LIXT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Jul 6

Lixte Biotechnology Holdings, Inc. has completed a corporate name change to NOMAD Power Solutions, Inc. and will begin trading under the new Nasdaq symbol NMAD.
The market has been experiencing a significant decline in the stock price of LIXT, with a drop of 5.997392438070404% to $7.21.
The name change and the market's reaction to it may be a significant event in determining the future market price of NOMAD Power Solutions, Inc.

Generated by AI

Sentiment

Of the messages about LIXT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	96.55% +6.65
Bearish	—	—	—	3.45% -6.65

Bullish· Jul 10

LIXT's recent announcements and funding have significantly boosted its short-term growth potential.
The company's advancements in clinical trials and securing new partnerships are driving the stock's rise.
LIXT's technology is currently underpriced, and a decent volume push could take the stock to $4 and then $5.

Bearish· Jul 3

Lixte Biotechnology Holdings, Inc. (LIXT) may experience a significant price drop if it fails to hold above $3.38.
Short covering at $3.20 led to a decline in LIXT's price, indicating a lack of buyers and a potential lack of profit.
LIXT has received a large "smart money" net outflow, resulting in a $526.41K loss and a 40.10% price change.

Generated by AI

Topics

Of the messages about LIXT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	81.36%
Technical Analysis	0%	0%	0%	4.3%
Analysts	0%	0%	0%	13.62%
Controversies	0%	0%	0%	0.72%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%

Announcements· Apr 17

Lixte Biotechnology Holdings, Inc. (LIXT) is positioning its LB-100 as a novel approach in the cancer treatment landscape.
The company is advancing precision oncology with LB-100 and strengthening its position through a partnership with Liora Technologies.
LIXT's LB-100 is a potential treatment for cancer, with the company positioning it as a novel approach in the field of oncology.

Technical Analysis· Jul 4

LIXT's price surged from $2 to $4, with a significant increase in volume and a strong RSI reading, indicating explosive momentum.
The stock's chart pattern showed a bullish breakout, with the RSI hitting the sweet spot and volume skyrocketing, catching the attention of chart watchers.
LIXT's technical analysis suggests strong momentum, with the stock breaking through key resistance and RSI signaling super strength, indicating a potential continuation of the bullish trend.

Generated by AI

Community

Of the messages about LIXT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	40.48%
Newcomers	0%	0%	0%	59.52%

Regulars· Jul 3

Lixte Biotechnology Holdings, Inc. ($LIXT) saw a 55% increase after closing a $5M private placement and experiencing a surge in volume, nearly 9M traded.
The company's lead drug, LB-100, is showing early promise in cancer research, with a low float and fresh capital signaling a bright future in biotech.
The stock's strong momentum is attributed to its bullish chart patterns, with the RSI (Relative Strength Index) signaling strength and a breakout in volume, indicating a potential liftoff setup.

Newcomers· Jul 3

The newcomers are focused on the potential for Lixte Biotechnology Holdings, Inc. (LIXT) to reach prices above $4 and possibly even $5 per share.
They are concerned about taking profits and managing risk, as the stock's volume is "insane" and it can come down quickly.
The newcomers are predicting a "green day" and expecting LIXT to hit $4 per share, with one user even claiming it will fly on VWAP support.

Generated by AI

Lixte Biotechnology Holdings

Social

Jul 6

Sentiment

Bullish· Jul 10

Bearish· Jul 3

Topics

Announcements· Apr 17

Technical Analysis· Jul 4

Community

Regulars· Jul 3

Newcomers· Jul 3

News

NOMAD Power Solutions Strengthens Subsidiary Executive Leadership

AI Energy Pivot Complete: LIXTE Biotechnology Finishes Corporate Rebrand to NOMAD Power Solutions, Begins Trading Under Nasdaq: NMAD

LIXTE Completes Corporate Name Change to NOMAD Power Solutions, Inc.; To Begin Trading Under New Nasdaq Symbol NMAD

12 Health Care Stocks Moving In Thursday's After-Market Session - Seer (NASDAQ:SEER), Universe Pharmaceut

Also Discussed

Lixte Biotechnology Holdings Inc.

Company Information

Location

News

NOMAD Power Solutions Strengthens Subsidiary Executive Leadership

AI Energy Pivot Complete: LIXTE Biotechnology Finishes Corporate Rebrand to NOMAD Power Solutions, Begins Trading Under Nasdaq: NMAD

LIXTE Completes Corporate Name Change to NOMAD Power Solutions, Inc.; To Begin Trading Under New Nasdaq Symbol NMAD

12 Health Care Stocks Moving In Thursday's After-Market Session - Seer (NASDAQ:SEER), Universe Pharmaceut

Also Discussed

Social

Jul 6

Sentiment

Bullish· Jul 10

Bearish· Jul 3

Topics

Announcements· Apr 17

Technical Analysis· Jul 4

Community

Regulars· Jul 3

Newcomers· Jul 3